Salute e Benessere

Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates…

– Xywav® revenues grew 13% year-over-year, with robust net patient adds of 625 quarter-over-quarter – – Xywav® revenues grew 13% year-over-year, with robust net patient adds of 625 quarter-over-quarter – – Zepzelca® granted Priority Review in 1L ES-SCLC – DUBLIN , Aug. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2025 and updated financial guidance for 2025. "It has been a privilege to lead...
PR Newswire
05/08/2025

Press release: CMS Approves Additional Payment for Sequana Medical’s alfapump®…

CMS Approves Additional Payment for Sequana Medical’s alfapump® system in Hospital Inpatient Casesalfapump® New Technology Add-on Payment (NTAP) Included in CMS Final Fiscal Year 2026 Rule and in effect by October 1, 2025NTAP provides for up to $21,450 when performed in the hospital inpatient settingalfapump® US commercial launch remains on track for Q3 2025 through specialty commercial team focused on liver transplant centersGhent, Belgium – 5 August 2025 –...
Nasdaq GlobeNewswire
05/08/2025

VALNEVA Declaration of shares and voting rights: July 31, 2025

VALNEVADeclaration of shares and voting rightsJuly 31, 2025__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: August 5, 2025 Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights* Description of the...
Nasdaq GlobeNewswire
05/08/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2025

Aggregatedpresentationbydayandbymarket Statement of transactions in own shares from July 28th to August 1 st2025 Name of the issuerIdentity code of the issuer (Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P11...
Nasdaq GlobeNewswire
05/08/2025

Morphic Medical Announces CEO Transition

The Board of Directors is pleased to announce that Mike Gutteridge will assume the role of CEO, bringing with him a wealth of experience in the bariatric endoscopy space. Mike most recently served as Vice President of Therapy Development and Commercial Operations at Morphic where he developed the companies go-to-market strategy for RESET®. The Board of Directors is pleased to announce thatMike Gutteridgewill assume the role of CEO, bringing with him a wealth of experience in the bariatric...
PR Newswire
05/08/2025

MarketsandMarkets' 360Quadrants Recognizes Top Startups and SMEs in the Pharmacy…

Company Highlights in the Pharmacy Automation Startups/SMEs Companies Assessment: Company Highlights in the Pharmacy Automation Startups/SMEs Companies Assessment: To explore the full quadrant report and see how companies are positioned in the Pharmacy Automation Startups/SMEs Companies Assessment, 2025, Visit:https://www.360quadrants.com/healthcare/pharmacy-automation-startups Evaluation Criteria The vendor evaluation was conducted on over 70 companies, of which the...
PR Newswire
05/08/2025

Biomaterials Market to Grow at a CAGR of 15.5% from 2025 to 2032 | SkyQuest…

Get Free Sample Copy of the Report: https://www.skyquestt.com/sample-request/biomaterials-market Get Free Sample Copy of the Report:https://www.skyquestt.com/sample-request/biomaterials-market Biomaterials Market Key Growth Drivers The biomaterials market is experiencing robust growth driven by a convergence of factors that highlight the increasing demand for advanced medical solutions. One of the most prominent drivers is the rising global prevalence of chronic diseases, such as...
PR Newswire
05/08/2025

Cell Culture Market to Reach USD 71.1 Billion by 2032, Says SkyQuest Technology…

Get a Free Sample Report - https://www.skyquestt.com/sample-request/cell-culture-market Get a Free Sample Report -https://www.skyquestt.com/sample-request/cell-culture-market Cell Culture Market Key Growth Drivers Biopharmaceutical companies depend on advanced cell culture systems to produce safe and effective biologics. Use of monoclonal antibodies, vaccines, and recombinant proteins is rising rapidly around the world. As chronic diseases, cancers, and autoimmune disorders...
PR Newswire
05/08/2025

Liquid Biopsy Market worth US$7.05 billion by 2030 with 11.8% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 Browse in-depth TOC on "Liquid Biopsy Market" 486 - Tables 60 - Figures 393 - Pages By technology,the liquid biopsy market is segmented by technology into multi-gene parallel analysis using NGS and single-gene analysis using PCR & microarrays. In 2024, the multi-gene parallel analysis using...
PR Newswire
05/08/2025

With 6.4% CAGR, Extracorporeal CO2 Removal Devices Market to Reach US$184.36…

Extracorporeal CO₂ removal systems are primarily utilized in critical care involving patients with acute respiratory failure and COPD. Extracorporeal CO₂ removal devices allow clinicians to undertake lower-set ventilator parameters and diminish ventilator-induced lung injuries. Extracorporeal CO₂ removal systems are primarily utilized in critical care involving patients with acute respiratory failure and COPD. Extracorporeal CO₂ removal devices allow clinicians to undertake lower-set…
PR Newswire
05/08/2025

Topical Drug Delivery Market US$409.0 Billion Forecast by 2030 with 8.8% CAGR |…

Browse in-depth TOC on "Topical Drug Delivery Market" Browse in-depth TOC on "Topical Drug Delivery Market" 468 - Tables 71 - Figures 435 - Pages By product,the topical drug delivery market is segmented into semi-solid formulations, liquid formulations, solid formulations, transdermal products, and other products. Other products include stick, aerosol (spray), and foam. The large share of the semi-solid formulations segment is attributed to its convenience and ease of...
PR Newswire
05/08/2025

Cardiovascular Echocardiography Market is Expected to Reach US$222.14 Million by…

The cardiovascular echocardiography market analysis focuses on advancements such as 3D/4D echocardiography, strain imaging, and AI-powered diagnostic tools. These advancements are expected to play a vital role in the market growth in the coming years. The report runs an in-depth analysis of market trends, key players, and future opportunities. The cardiovascular echocardiography market analysis focuses on advancements such as3D/4D echocardiography , strain imaging ,and AI-powered...
PR Newswire
05/08/2025

Seegene Unveils CURECA™ and STAgora™ at ADLM 2025, Advancing the Next Stage of…

"With CURECA™ and STAgora™, we are taking an important step toward the future of diagnostics," said Dr. Jong-Yoon Chun, Chairman and CEO of Seegene, during a press conference with U.S. and global media on July 30. "Our goal is to enable laboratories worldwide to automate complex testing workflows and use diagnostic data more effectively, ultimately helping advance global efforts toward a world free from diseases." "With CURECA™ and STAgora™, we are taking an important…
PR Newswire
05/08/2025

Tecan schedules conference call on August 12th to discuss half year 2025…

Männedorf, Switzerland, August 5, 2025 –The Tecan Group AG (SIX Swiss Exchange: TECN) will hold a conference call to discuss the financial results for the first half year 2025 on Tuesday, August 12th, 2025 at 08:30 CEST. The results will be published on August 12th, 2025 at 6:00 CEST.The conference call will be audio-webcast with synchronized presentation slides. The webcast and a replay of the webcast will be made available in the "Investor Relations" section of Tecan's websitewww...
Nasdaq GlobeNewswire
05/08/2025

Court Sides with Cardiovalve in Edwards patent spat

Case Background Case Background The dispute centered on Edwards' challenge to the validity of Cardiovalve's U.S. Patent No. 10,702,385 ("'385 Patent") covering an innovative transcatheter heart valve clamping and support structure for minimally invasive mitral and tricuspid valve therapies. OnJune 2, 2021, Edwards petitioned for inter partes review of claims 1-10 of that patent. PTAB issued Final Written Decision allowing Cardiovalve's motion to amend claims after Edwards failed...
PR Newswire
05/08/2025

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate…

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate UpdateThree active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical developmentACI-7104.056 anti-alpha-synuclein active immunotherapy in Parkinson’s disease produced strong immunogenicity and favorable safety profile in interim results from the ongoing Phase 2 VacSYn reported in April, with further data to come in H2 2025Third Alzheimer’s disease cohort...
Nasdaq GlobeNewswire
05/08/2025

MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and…

Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in mid-2026Other clinical trials of sonelokimab in palmoplantar pustulosis (PPP), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA) and adolescent HS progressing well and expected to support a catalyst-rich roadmap over the next 12 monthsEnded the second quarter with $425...
Nasdaq GlobeNewswire
05/08/2025

SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve…

"We are proud to deepen our partnership with AstraZeneca through this significant new initiative, which highlights the growing demand for secure, compliant, and scalable real-world AI applications," said Ross Muken, President of SOPHiA GENETICS. "Our platform is purpose-built to manage complex healthcare data environments, and this collaboration reinforces our shared commitment to driving better patient outcomes through trusted, federated analytics powered by data and AI."…
PR Newswire
05/08/2025

ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT JULY 2025

Accumulated revenue for January – July 2025 increased by 57 % to SEK 1,780.1 (1,130.7) million. Accumulated revenue for January –July 2025increased by 57 % toSEK 1,780.1(1,130.7) million. Revenues were distributed as follows: Countries in regions: -The Nordics:Denmark, Faroe Island,Finland,Iceland,Norway,Sweden- Central Europe :Austria,Germany,Switzerland- East Europe :Czech Republic,Slovakia,Hungary,Poland,Romania-South &West...
PR Newswire
05/08/2025

Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic…

Designed for applications such as hematopoietic disease modeling, drug screening and hematotoxicity studies, TrailBio® Hematopoietic Progenitor Cells enable a reliable human model system that eliminates donor variability and supports reproducible results. Designed for applications such as hematopoietic disease modeling, drug screening and hematotoxicity studies, TrailBio ®Hematopoietic Progenitor Cells enable a reliable human model system that eliminates donor variability and supports...
PR Newswire
05/08/2025

LA ROCHE-POSAY AND GLOBAL SKIN HEALTH EXPERTS UNITE TO WARN ABOUT LONG TERM…

LA ROCHE-POSAY REAFFIRMS ITS LONGSTANDING COMMITMENT TO SKIN HEALTHAs a global leader in sun protection and skin cancer prevention, La Roche-Posay is worried about the long-term consequences of the Burn Lines challenge and aims at warning the public of how dangerous this practice can be, alongside health professionals. LA ROCHE-POSAY REAFFIRMS ITS LONGSTANDING COMMITMENT TO SKIN HEALTHAs a global leader in sun protection and skin cancer prevention, La Roche-Posay is worried about the...
PR Newswire
05/08/2025

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial…

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency (EMA) orphan drug designation, enabling readiness for initiation across sites in both the U.S. and EuropePS-002, Purespring’s lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy and is supported by a wealth of preclinical dataLondon...
Nasdaq GlobeNewswire
05/08/2025

Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan

Press ReleaseNicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan Exclusive Japanese partner Kowa has initiated a Phase 3 safety clinical trial of NCX 470 for the treatment of ocular hypertension in JapanTriggers a €2 million milestone payment to Nicox August 5, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive...
Nasdaq GlobeNewswire
05/08/2025

Kuros Biosciences launches MagnetOs MIS Delivery System by completing first…

Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearanceSchlieren (Zürich), Switzerland, August 5, 2025– Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced the completion of the first U.S. cases using the new MagnetOs TMMIS Delivery System – a sterile, prefilled, single-use delivery system engineered for Minimally Invasive Surgery...
Nasdaq GlobeNewswire
05/08/2025
Altri  Comunicati